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Purpose	  :	   Secondary	   malignancies	   (SM)	   are	   a	   known	   long-­‐term	   problem	   in	   children	  surviving	  brain	  tumors.	  We	  report	  on	  two	  unusual	  cases	  of	  SM	  observed	  after	  treatment	  of	   ependymoma.	   	   Case	   reports	  :	   1.	   The	   first	   case	   is	   a	   female	   survivor	   of	   a	   low-­‐grade	  ependymoma	  	  (Grade	  II).	  She	  had	  been	  treated	  at	  the	  age	  of	  3	  months	  with	  surgery	  and	  chemotherapy.	  A	  relapse	  of	   the	  primary	   tumor	  happened	  two	  years	   later,	   	  which	   	  was	  completely	  removed	  and	  treated	  with	  	  local	  radiotherapy	  to	  the	  posterior	  fossa.	  	  Fifteen	  years	   after	   the	   first	   cancer,	   she	   developed	   a	   pontine	   glioma	   near	   the	   location	   of	   the	  previous	  radiotherapy.	  2.	  The	  second	  case	  is	  a	  femal	  survivor	  of	  an	  ependymoma	  (Grade	  III)	  which	  was	  removed	  and	  irradiated	  when	  she	  was	  4	  years	  old.	  The	  child	  developed	  a	  pontine	   glioma	   near	   the	   location	   of	   the	   previous	   radiotherapy	   ten	   years	   after	   the	  diagnosis	  of	  the	  first	  cancer.	  Further	  extension	  of	  the	  disease	  showed	  after	  biopsy	  PNET-­‐like	  features.	  Both	  patients	  passed	  away.	  	  
Discussion	  and	  Conclusion	  :	  Second	  malignant	  neoplasia	  is	  a	  rare	  phenomenon	  and	  this	  risk	  should	  not	  overshadow	  the	  great	  success	  in	  treating	  cancer	  of	  childhood.	  Among	  the	  studied	   risk	   factors,	   young	   age	   and	   radiotherapy	   are	   well	   established.	   The	   reported	  	  patients	   were	   followed	   annually	   to	   ensure	   their	   remission	   and	   	   both	   developed	  symptoms	  and	  an	  unusual	  unreported	  secondary	  cancer	  a	  few	  months	  after	  the	  annual	  monitoring	   that	   was	   considered	   as	   normal.	   This	   issue	   highlights	   the	   complexity	   of	  monitoring	  cancer	  survivors	  and	  raises	  the	  question	  of	  the	  best	  way	  for	  their	  long-­‐term	  follow-­‐up.	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INTRODUCTION	  Central	  nervous	  system	  (CNS)	  neoplasia	  is	  the	  second	  most	  frequent	  cancer	  in	  children	  between	   1	   year	   and	   19	   years	   old(1).	   In	   the	   United	   States,	   the	   estimated	   incidence	   of	  childhood	  CNS	  cancer	  is	  4.5	  cases	  per	  100'000	  person-­‐years	  for	  children	  below	  19	  years	  old	  (2).	   In	   the	   last	   four	  decades,	   the	  survival	  rate	   for	  CNS	  malignancy	  has	  significantly	  improved	  with	   a	   global	   survival	   up	   to	   74%	  at	   5	   years,	   	   due	   to	   the	   improved	   surgery,	  radiotherapy	  and	  chemotherapy(3).	  All	  these	  treatments	  are	  associated	  with	  risks	  of	  long-­‐term	  morbidity	  and	  late	  mortality,	  such	   as	   early	   death,	   organ	   dysfunction,	   reduced	   growth	   and	   development,	   decreased	  fertility,	  	  cognitive	  dysfunction	  or	  second	  malignancy.	  In	  the	  Childhood	  Cancer	  Survivor	  Study	  (CCSS)	  Cohort	  ,	  the	  most	  frequent	  second	  malignancies	  after	  a	  primary	  CNS	  cancer	  are	  in	  order	  of	  frequency	  other	  CNS	  tumors,	  thyroid	  cancer	  and	  soft	  tissue	  sarcomas(4).	  	  We	  report	  on	  two	  cases	  of	  female	  patients	  who	  developed	  a	  pontine	  glioma	  a	  few	  years	  after	   an	   intracranial	   ependymoma	   treated	  with	   surgery	   and	   irradiation.	   	   As	   far	   as	  we	  know,	  a	  similar	  case	  has	  not	  yet	  been	  described.	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CASES	  REPORTS	  Patient	  1	  :	  A	  10-­‐week-­‐old	  baby	  girl	  presented	   in	  November	  1995	  with	  respiratory	  distress,	   fever,	  feeding	   difficulties,	   vomiting	   and	   a	   six	   days	   history	   of	   right	   peripheral	   facial	   paresis.	  Physical	  examination	  demonstrated	  paralysis	  of	  the	  velum	  on	  the	  right	  side,	  explaining	  the	   difficulty	   in	   swallowing.	   The	   day	   of	   the	   admission,	   one	   episode	   of	   opisthotonos	  happened	  and	  she	  had	  to	  be	   intubated	  as	  a	  result	  of	  breathing	  difficulties.	  Cerebral	  CT	  showed	  a	  posterior	  fossa	  tumor	  with	  obstuctive	  hydrocephalus,	  bone	  deformation	  and	  	  a	  secondary	   compression	   of	   the	   brain-­‐stem.	   MRI	   confirmed	   the	   findings	   suggesting	   an	  ependymoma.	  At	  surgery,	   the	  tumor	   	  was	  situated	   in	   the	   IVth	  ventricle	  with	  extension	  into	  the	  cisterna	  magna	  under	  the	  amygdalia	  and	  into	  the	  right	  cerebello	  pontine	  angle	  and	   could	   only	   be	   subtotally	   (90%)	   removed	   by	   an	   osteoplastic	   craniotomy	   of	   the	  posterior	   fossa.	   An	   otolaryngological	   examination	   showed	   a	   right	   vocal	   cord	   paresis.	  After	  the	  surgery,	  facial	  paresis	  and	  tongue	  sensibility	  disorder	  persisted.	  There	  weren’t	  other	   neurological	   sequela.	   Neuropathological	   diagnosis	   was	   for	   low-­‐grade	  ependymoma	  (WHO	  Grade	  II).	  The	  child	  entered	  the	  protocole	  Baby	  POG	  92-­‐33	  and	  was	  treated	   with	   chemotherapy	   only	   (vincristine,	   cyclophosphamide,	   etoposide)	   from	  November	  1995	  to	  June	  1997.	   	  In	  September	  1997,	  at	  the	  age	  of	  2	  years	  and	  3	  months	  after	   end	   of	   treatment,	   the	   child	   presented	   a	   local	   	   relapse	  which	   could	   be	   	   removed	  completely.	  Histology	  was	   identical	  with	   the	  primary	  disease.	   	  She	   received	   then	   local	  radiatiotherapy	   to	   the	  posterior	   fossa	  with	  180	  cGy/day	  up	   to	  a	   total	  dose	  of	  50.4	  Gy.	  The	   child	   remained	   disease-­‐free	   until	   September	   2010.	   However,	   she	   presented	  numerous	   problems	   related	   to	   disease	   and	   treatment	   such	   as	   	   long-­‐term	   feeding	   by	  percutaneous	   gastroenterotomy,	   neurocognitive	   difficulties	   needing	   special	   schooling,	  	  moderate	  hearing	  loss	  and	  precocious	  puberty	  	  at	  the	  age	  of	  8.	  In	   September	   2010,	   12	   years	   after	   end	   of	   treatment,	   the	   girl	   developed	   nausea,	  	  regurgitations	  with	  hiccup	  and	  reported	  a	  loss	  of	  weight	  with	  an	  unusual	  tiredness	  since	  July	   2010.	   Her	   appetite	   decreased	   and	   	   odynodysphagia	   appeared	   with	   difficulty	   to	  swallow	  solid	  food	  and	  with	  frequent	  nasal	  discharge.	  Progressive	  balance	  disorders	  and	  dizziness	  were	   other	   complaints.	   	   Physical	   examination	   revealed	   discrete	   tremor	   and	  ataxia	   and	   an	   horizontal	   nystagmus.	   MRI	   showed	   an	   expansive	   process	   involving	   the	  ponto-­‐bulbar	   region	   with	   compression	   of	   the	   fourth	   ventricle,	   suggestive	   of	   pontine	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glioma	   (Figures	   1.1,	   1.2).	   	   As	   the	   tumor	   was	   unresectable,	   the	   girl	   was	   put	   on	  Temozolomide	   90mg/m2/d	   	   and	   radiotherapy	   (total	   dosis	   40	   Gy),	   followed	   by	  Temozolomide	  only	  (200mg/m2/d	  5	  days	  per	  month).	  However,	  tumor	  progressed	  and	  the	  child	  passed	  away	  4	  months	  after	  diagnosis	  of	  the	  secondary	  cancer.	  	  Figure	   1.1	  :	   expansive	   process	   involving	   the	   ponto-­‐bulbar	   region	  with	   compression	   of	  the	  fourth	  ventricle,	  suggestive	  of	  pontine	  glioma	  (September	  2010)	  Transverse	  view	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Figure	  1.2	  :	  Sagittal	  view	  	  (September	  2010)	  
	  	  Patient	  2	  :	  	  A	   4-­‐year-­‐old	   girl	   presented	   in	   April	   1997	   with	   a	   2-­‐months-­‐history	   of	   biparietal	  headaches	   and	   a	   disorder	   of	   equilibrium	   with	   a	   lightheaded	   walking	   and	   falls	   for	   2	  weeks.	   A	   few	   episodes	   of	   vomiting	   were	   reported	   as	   well.	   The	   physical	   examination	  	  showed	  a	  bilateral	  papillary	  edema	  with	  a	  left	  horizontal	  and	  vertical	  nystagmus.	  There	  were	   neither	   signs	   of	   strabismus	   nor	   meningism	   and	   the	   audition	   was	   normal.	   She	  conserved	   strenght	   of	   the	   four	   limbs.	   An	   MRI	   made	   end	   of	   April	   1997	   showed	   an	  obstructive	   hydrocephalus	   with	   a	   voluminous	   tumor	   in	   the	   posterior	   fossa,	   with	  heterogeneous	  contrast	  enhancement.	  A	  subtotal	  resection	  because	  of	  proximity	  to	  the	  brainstem	  was	  performed	  	  a	  few	  days	  after	  the	  craniospinal	  imaging	  and	  introduction	  of	  a	  ventricular	  drain.	  The	  pathology	  	  showed	  an	  anaplastic	  ependymoma	  of	  the	  posterior	  fossa	   and	   the	   IVth	   ventricle,	   OMS	   grade	   III.	   After	   	   surgery	   the	   patient	   presented	   	   left	  central	   facial	  paresis,	   	   a	  bilateral	  oculomotor	  paresis	   (specially	  abduction	   to	   the	  right)	  with	   a	   bilateral	   limitation	   of	   horizontal	   movements	   and	   a	   transient	   mutism	   as	  postoperative	   complications.	   Another	   postoperative	   	   complication	   was	   transient	  	  cortical	   post	   ischemic	   blindness	   	   due	   to	   the	   blood	   loss	   during	   surgery	   with	   rapid	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recovery	   	   within	   a	   few	   days.	   Left	   facial	   paresis,	   vertical	   right	   sided	   nystagmus	   and	  cerebellar	  ataxia	  persisted	  but	  were	  less	  important	  than	  before.	  Postoperative	  	  CT-­‐scan	  	  didn’t	  show	  a	  tumor	  residue.	  One	  	  month	  later,	  the	  patient	  showed	  still	  slight	  central	  left	  facial	  paresis,	  discrete	  ataxia	  and	  horizontal	  limitation	  of	  ocular	  movements	  and	  a	  new	  slight	  right	  convergent	  strabismus	  ,	  whereas	  she	  had	  recovered	  from	  mutism.	  Treatment	  was	  completed	  by	  local	  radiotherapy	  at	  a	  total	  dose	  of	  	  54	  Gy	  by	  isocentric	  technique	  at	  first.	   The	   region	   of	   the	   tumor	   including	   a	   safety	   margin	   (2cm)	   was	   treated	   by	   four	  oblique	  beams	  with	  a	  1.8	  Gy	  per	   fractionated	  sessions,	  5	  sessions	  per	  week	   for	  a	   total	  dose	  of	  50.4	  Gy,	  and	  a	  	  boost	  at	  the	  residual	  tumor	  made	  by	  two	  opposed	  lateral	  beams	  for	   a	   total	   dose	   of	   54	  Gy.	  Whereas	   oculomotor	   disturbances	   and	   cerebellar	   syndrome	  persisted,	  however	  improving,	  the	  child	  remained	  in	  complete	  remission	  of	  disease	  until	  April	   2007.	   Follow-­‐up	   was	   marked	   by	   a	   strabismus	   operation,	   learning	   and	  concentration	   difficulties	   needing	   a	   special	   schooling	   and	   hormone	  deficiencies	  which	  led	  to	  a	  growth	  hormone	  treatment	  started	  in	  	  2004.	  After	   10	   years	   of	   disease-­‐free	   follow-­‐up,	   in	   April	   2007,	   	   the	   girl	   presented	   new	  neurological	  symptoms	  such	  as	  language	  disorder,	  new	  balance	  disorder	  with	  falls	  and	  headache.	  At	  clinical	  examination,	  she	  presented	  ataxia,	  dysarthria	  and	  pronounced	  left	  facial	  paresis.	  MRI	  showed	  a	  new	  pontine	  mass	  (Figure	  2),	  predominant	  on	  the	  right	  side	  with	  peripheral	  contrast	  enhancement	  	  suggesting	  a	  glial	  tumor	  rather	  than	  a	  relapse	  of	  the	   first	   ependymoma.	   (1.5x6	  mm)	  As	   the	   tumor	  was	   inoperable,	   	   and	  with	   regard	   to	  previous	  radiotherapy,	   it	  was	  decided	   to	  administer	  VP-­‐16	  and	   temozolomide	  without	  	  proceeding	   to	   a	   biopsy	   because	   of	   high	   risk	   of	   local	   	   complications.	   	   After	   initial	  	  improvement	   during	   four	   months,	   	   neurological	   symptoms	   worsened	   	   due	   to	   tumor	  progression	  on	  MRI	  	  with	  appearance	  of	  2	  new	  tumor	  nodules	  in	  the	  left	  frontal	  	  region	  and	   right	   internal	   capsule.	   (Figure	   3.1,	   3.2)	   As	   clinical	   symptoms	   increased	   with	   left	  hemiparesis,	   facial	   paresis	   of	   the	   left	   side	  marked	  with	   dysarthria,	   important	   balance	  disorder	   with	   frequent	   falls	   and	   aggressiveness,	   it	   was	   decided	   to	   perform	   a	   PET-­‐CT	  confirming	   	   malignant	   	   activity	   in	   the	   several	   locations.	   Considering	   this	   unusual	  evolution,	  a	  stereotactic	  biopsy	  was	  performed.	  Pathological	  report	  of	  the	  biopsy	  noted	  the	   presence	   of	  malignant	   tumor	  with	   neuroglial	   components,	   criteria	   for	   PNET	  were	  partially	   fulfilled	   by	   the	   high	   clinical	   aggressiveness,	   the	   immunohistochemical	  constellation	   and	   cell	   proliferation	   extreme	   (Mib>	   70%)	   Brain	   tissue	   was	   largely	  infiltrated	   by	   highly	   atypical	   tumor	   cell	   proliferation	   with	   multinucleated	   giant	   cells,	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many	  images	  of	  pycnoses	  and	  mitoses,	  and	  some	  atypical	  mitoses.	  There	  was	  no	  active	  vascularisation	   in	   the	   tumor	   or	   visualized	   necrosis.	   	   The	   clinical	   context	   continued	   to	  worsen	  with	  a	   left	  hemisyndrome,	  a	  massive	  dysarthia	  with	  difficulty	   to	   	   swallow	  and	  weakness	  on	  the	  contralateral	  side.	  MRI	  confirmed	  a	  massive	  growth	  of	  the	  entire	  tumor	  disease,	   invading	   the	   cerebellar	   peduncles	   on	   both	   sides,	   medulla,	   midbrain	   and	  diencephalon	   greater	   right	   than	   the	   left.	   We	   could	   note	   an	   intraventricular	   fluid	  dissemination	   by	   appearance	   of	   a	   new	   nodule	   of	   the	   right	   frontal	   horn	   and	   a	   new	  rupture	   of	   the	   blood-­‐brain	   barrier	   at	   known	   tumor	   infiltration	   next	   to	   the	   left	   frontal	  horn.	   	   After	   the	   stereotactic	   biopsy,	   mutism,	   aphasia,	   incontinence	   and	   difficulty	   in	  swallowing	   appeared	   as	   consequences	   of	   the	   tumor	   progression.	   Because	   of	   the	   poor	  prognosis,	  it	  was	  decided	  to	  accompany	  the	  child	  with	  palliative	  care.	  She	  passed	  away	  in	  November	  2007.	  	  Figure	  2.1	  :	  new	  pontine	  mass,	  predominant	  on	  the	  right	  side	  with	  peripheral	  contrast	  enhancement	  	  suggesting	  a	  glial	  tumor	  (April	  2007)	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Figure	  3.1	  :	  new	  tumor	  nodules	  in	  the	  left	  frontal	  	  region	  (October	  2007)	  
	  	  Figure	  3.2	  :	  new	  tumor	  nodules	  in	  the	  internal	  capsule	  (October	  2007)	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DISCUSSION	  Our	  two	  patients	  were	  diagnosed	  for	  ependymoma	  of	  the	  posterior	  fossa	  in	  childhood,	  that	  were	  mainly	  treated	  with	  surgery	  and	  radiotherapy.	  The	  youngest	  patient	  benefited	  from	   chemotherapy	   to	   delayed	   radiotherapy.	   After	   a	   decade	   of	   remission,	   both	  developped	   a	   secondary	   malignancy,	   radiologically	   diagnosed	   as	   	   pontine	   glioma.	   .	  Whereas	   in	   the	   the	   first	   patient	   the	   tumor	   behaved	   as	   such,	   the	   second	   patient	  developped	  in	  addition	  to	  the	  pontine	  tumor	  other	  tumors	   	  that	  could	  be	  biopsied	  and	  showed	  features	  of	  a	  PNET.	  	  Second	  cancer	  is	  one	  of	  the	  highest	  impacts	  on	  morbidity	  and	  mortality	  in	  children	  who	  had	  a	  neoplasia	   in	   the	  past.	  With	  higher	  cure	  rates,	   increasing	  cumulative	   incidence	  of	  second	  malignant	  neoplasia	  is	  observed	  with	  3.2%	  at	  20	  years	  in	  2001(9)	  and	  9.3%	  30-­‐year	   cumulative	   incidence	   in	   2007	   (4).	   In	   the	   Nordic	   population-­‐based	   case	   control	  study,	  the	  	  relative	  risk	  for	  patients	  to	  develop	  a	  second	  cancer	  was	  3.6-­‐fold	  compared	  to	  the	   general	   population	   (10)	   and	   5-­‐fold	   relative	   risk	   of	   second	   maligancies	   among	  survivors	   in	   British	   Columbia	   study(11).	   Furthermore	   CNS	   tumors	   suvivors	   are	   	   at	  highest	   risk	  of	  death	  compared	   to	  other	  childhood	  cancer	  with	  a	  cumulative	  mortality	  rate	   of	   16.8%	   at	   20	   years.(12).	   In	   the	   CCSS,	   0.05%	   of	   children	   with	   primary	   cancer	  presented	  a	  second	  malignancy.	  (N=14’358).	  Among	  the	  CNS	  tumors	  (N=1877),	  0.036%	  presented	   a	   second	   cancer,	   0.26%	   of	   whom	   were	   a	   second	   CNS	   tumors.(4)	   In	   the	   5	  Nordic	   Countries	   study,	   0.011	   %	   of	   survivors	   developed	   a	   second	   cancer.	  (N=25'120)(10).	   Meningiomas	   are	   the	   most	   frequent	   second	   neoplasms	   observed	  	  survivors	   of	   primary	   CNS	   neoplasms(13).	   	   We	   didn’t	   find	   any	   case	   report	   in	   the	  literature	  that	  matched	  with	  our	  two	  patients.	  So	  these	  two	  cases	  are	  interesting	  by	  their	  unusual	  location	  of	  second	  neoplasia	  in	  the	  pons.	  Literature	  about	  second	  malignancies	  reported	  various	  clues	  as	  possible	  risk	  factors	  and	  we	  are	  reporting	  some	  elements	  that	  seem	  interesting	  to	  us.	  Ependymomas	   develop	   from	   primitive	   glia.	   They	   are	   mostly	   located	   in	   the	   brain,	  typically	  in	  posterior	  fossa	  or	  in	  the	  fourth	  ventricle,	  but	  can	  also	  present	  as	  	  spinal	  cord	  tumors	   .(5)	   	  Their	   incidence	  of	   0.23	  per	  100'000	  person-­‐years	   represent	   only	  10%	  of	  CNS	  tumors	  in	  children.	  (6)	  Males	  and	  females	  are	  equally	  concerned	  by	  this	  neoplasia	  and	   the	   	  median	   age	   at	   diagnosis	   is	   	   5	   years.	   The	  World	   Health	   Organization	   (WHO)	  classification	   of	   CNS	   tumors	   divides	   ependymal	   tumors	   into	   four	   subtypes	  :	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subependymoma	   (WHO	   grade	   I),	   myxopapillary	   ependymoma	   (WHO	   grade	   I),	  ependymoma	  (WHO	  grade	  II)	  and	  finally	  anaplastic	  ependymoma	  (WHO	  grade	  III).(7)	  The	   initial	   treatment	   for	   children	   with	   ependymoma	   consists	   of	   surgery	   followed	   by	  adjuvant	   radiotherapy.	   Chemotherapy	   does	   not	   have	   an	   important	   place	   in	   the	  treatment	   of	   this	   cancer	   but	   may	   play	   a	   role	   in	   young	   children	   to	   delay	   the	  radiotherapy.(5)	  Ependymoma,	  high	  grade	  glioma	  and	  medulloblastoma	  correlate	  with	  worse	   survival,	   compared	   with	   astrocytomas	   and	   low	   grade	   glioma.(8)	   When	   in	  remission,	   CNS	   cancer	   survivors	   have	   a	   higher	   risk	   of	   long-­‐term	   morbidity	   and	   late	  mortality	  compared	  with	  the	  general	  population,	  such	  as	  early	  death,	  organ	  dysfunction,	  impaired	  growth	  and	  development,	  decreased	  fertility,	  	  cognitive	  dysfunction	  or	  second	  malignancy,	  most	  of	  them	  correlated	  with	  the	  treatments(8)	  	  Second	   	   malignancies	   are	   caused	   by	   different	   factors,	   such	   as	   genetic	   predisposition,	  chemotherapy	  and	  radiotherapy.	  Moreover	  they	  are	  related	  as	  well	  to	  the	  age	  of	  patient	  at	  time	  of	  diagnosis	  and	  the	  histology	  of	  the	  tumor.	  The	   CCSS	   demonstrated	   a	   significant	   linear	   dose-­‐response	   relationship	   between	  radiotherapy	  dose	   and	  development	   of	   second	  CNS	   cancer	   such	   as	   gliomas	   (OR=6.78)	  and	  meningiomas	   (OR=0.94).	  They	  estimated	   the	  dose	  of	   irradiation	  of	  each	  child	  and	  matched	   it	   with	   control	   subjects	   on	   age,	   sex,	   and	   time	   since	   original	   cancer	  diagnosis.(13)	  They	  identified	  that	  children	  who	  survived	  of	  CNS	  neoplasms	  who	  were	  cured	   with	   CNS-­‐direct	   radiation	   >50	   Gy	   had	   a	   cumulative	   incidence	   of	   a	   second	   CNS	  cancer	  of	  7.1	  %	  (95%	  CI=4.5%	  to	  9.6%)	  at	  25	  years	  compared	  to	  1.0%	  (95%	  CI=0%	  to	  2.3%)	  among	  children	  who	  haven’t	  been	  	  treated	  with	  radiation.(14)	  The	  relative	  risks	  for	  doses	  above	  30	  Gy	  were	  RR=20	  for	  glioma	  and	  RR=50-­‐100	  for	  meningioma.(13)	  The	  5	   Nordic	   Countries	   study	   found	   an	   increased	   risk	   for	   children	   who	   received	  radiotherapy	  more	  than	  five	  years	  before	  the	  second	  cancer.	  There	  was	  a	  relative	  risk	  of	  1.8	  already	  from	  1	  Gy	  and	  increased	  up	  to	  18.3	  for	  doses	  above	  30	  Gy.	  In	  this	  study,	  the	  interval	  between	  the	  first	  and	  the	  second	  CNS	  cancer	  diagnose	  was	  8.8	  years.	  (15)	  It	  has	  to	  be	  underlined	  that	  patient	  1	  received	  a	  total	  dosis	  of	  50.4	  Gy	  et	  and	  patient	  2	  received	  54	  Gy.	  	  The	  main	  period	  to	  develop	  SM	  after	  radiotherapy	  is	  the	  interval	  of	  5-­‐9	  years	  from	  the	  diagnosis	   of	   the	   primary	   cancer	   (SMR	  :17.2,	   95%	   CI	  :14.7-­‐31.8)(8).	   The	   risk	   remains	  always	   higher	   than	   in	   the	   control	   population.	   Our	   two	   cases	   developed	   their	   second	  cancer	  15	  and	  10	  years	  after	  the	  primary	  diagnosis.	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Among	  risk	  factors	  studied,	  	  no	  significant	  association	  between	  chemotherapy	  exposure	  and	   CNS	   second	   cancer	   was	   found(13,16).	   However,	   combined	   with	   radiotherapy,	  chemotherapy	   	   could	   potentially	   contribute.	   .	   According	   to	   Svahn-­‐Tapper	   et	   al,	   the	  relative	  risk	   increased	   from	  2.3	  (95%	  CI	  1.4-­‐3.7)	   for	  radiotherapy	  only	   to	  4.3	  (95%	  CI	  2.6-­‐7.0)	  when	  radiotherapy	  was	  combined	  to	  chemotherapy(15).	  	  Although	  exposure	  to	  high	   doses	   of	   alkylating	   agents	   is	   associated	   with	   occurrence	   of	   second	   malignant	  neoplasia,	   this	   seems	   not	   to	   be	   the	  main	   factor	   for	   	   secondary	   	   CNS	   cancer.(4)	   .	   It	   is	  important	  to	  mention	  that	  it	  is	  very	  rare	  to	  cure	  CNS	  tumors	  with	  chemotherapy	  alone,	  without	  radiotherapy.	  	  The	   role	   of	   histology	   as	   risk	   factor	   for	   secondary	   cancer	   in	   	   long-­‐term	   survivors	   	  was	  studied	   by	   some	   investigators.	   They	   observed	   a	   statistically	   significant	   difference	  (P<.001)	  in	  mortality	  according	  to	  	  initial	  tumor	  histology,	  high-­‐grade	  glioma	  (estimated	  probability	   of	   death	   at	   10	   year	   32.6+-­‐10.7)	   and	   ependymoma	   (14.4+-­‐5.7)	   having	   the	  worse	  survival	  compared	  	  to	  other	  CNS	  tumors.(17)	  However,	  for	  the	  CCSS	  study	  and	  the	  5	   Nordic	   Countries	   Study,	   original	   CNS	   neoplasia	   diagnosis	   had	   no	   relation	   with	   the	  independant	  risk	  to	  develop	  a	  SMN	  when	  adjusted	  to	  the	  radiation	  dose.	  (10,13)	  	  Other	  risk	  factors	  are	  age	  under	  	  6	  years	  	  at	  irradiation	  because	  of	  the	  time	  of	  greatest	  brain	  tissue	  growth.	  (4)(10)	  Gender	  was	  another	  risk	  factors	  according	  to	  Svahn-­‐Tapper	  et	   al	   with	   significantly	   higher	   r	   risk	   of	   secondary	   cancer	   in	   female	   patients	   (RR	  =3.4,	  95%	  CI	  1.7-­‐6.8)	  compared	  	  to	  male	  patients.	  (1.3,	  95%	  CI	  0.7-­‐2.5)(15),	  which	  is	  difficult	  to	  explain.	  The	   carcinogenic	   effect	   of	   ionizing	   radiotherapy	   is	   well	   known,	   but	   	   its	   effect	   on	   the	  induced	  neoplasm	   is	  more	  difficult	   to	  establish	  and	   to	  quantify.	  The	  major	  problem	  of	  the	   studies	   is	   the	   lack	   of	   a	   sufficiently	   large	   patient	   group	   and	   the	   	   heterogeneity	   	   in	  order	   to	  match	   the	   patients	   with	   the	   controls.	   Furthermore,	   the	   quantification	   of	   the	  dose	   of	   radiotherapy	   is	   often	   hard	   to	   establish	   as	   treatment	   details	   are	   not	   always	  available.	   Moreover	   it	   is	   not	   mentioned	   in	   the	   studies	   in	   which	   context	   the	   second	  malignancies	   were	   diagnosed,	   whether	   the	   patients	   presented	   symptoms	   or	   the	  discovery	  was	  made	  during	  a	  planned	  clinical	  control.	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CONCLUSION	  In	   the	  CCSS	   cohort,	   about	   1.88	   additional	   cancer	   have	   	   been	  diagnosed	   for	   each	  1000	  children	   by	   years	   of	   follow-­‐up.(N	  =13'581)(9)	   Therefore,	   the	   second	   malignant	  neoplasia	   is	   a	   very	   rare	   phenomenon	   and	   that	   risk	   should	   not	   overshadow	   the	   great	  success	   in	   treating	   cancer	   of	   childhood.	   However,	   patients	   and	   health-­‐care	   providers	  must	  be	  aware	  of	  the	  risk	  of	  SMNs	  and	  must	  have	  a	  longterm	  surveillance,	  even	  more	  if	  they	  are	  concerned	  by	  established	  risk	  factors,	  such	  as	  radiotherapy.	  During	  the	  past	  35	  years,	  pediatric	  cancer	  treatment	  protocols	  have	  been	  changed	  to	  a	  better	   balance	   between	   toxicity	   and	   efficacy	   with	   the	   idea	   to	   minimize	   the	   use	   of	  radiation	   in	   children,	   as	   long	   as	   the	   treatment	   results	   are	   not	   compromised.	   Better	  technique	  will	  always	  emerge	  	  due	  to	  the	  technologic	  research	  to	  treat	  children	  with	  less	  negative	  effects	  on	  healthy	  tissues,	  as	  the	  available	  imaging	  techniques	  of	  radiotherapy	  for	  a	  precise	  definition	  of	  the	  target	  volume.	  These	  two	  patients	  were	   followed	  up	  annually	   to	  ensure	  their	  remission.	  Nevertheless	  both	  patients	  developed	  symptoms	  of	  the	  second	  cancer	  a	  few	  months	  after	  the	  annual	  monitoring	   that	   was	   considered	   as	   normal.	   This	   issue	   highlights	   the	   complexity	   of	  monitoring	  cancer	  survivors	  and	  rises	  the	  question	  of	  the	  best	  way	  to	  follow	  long-­‐term	  survivors.	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